Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.70 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.52 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL323824 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL1172743 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL3359435 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL2034678 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL8295172 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL5217474 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL323823 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL4126470 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| Hydrochloric Acid SCHEMBL5089207 | 0.98 | FFAR1 (0.68) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| Hydrochloric Acid SCHEMBL5089203 | 0.98 | FFAR1 (0.68) | FFAR1HDAC4ALDH1A1SLC9A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118290491-A | Copper nanocluster and preparation method thereof | 清华大学 | 2024-07-05 | — | — | CN | claimed |
| EP-1565190-A4 | ARYLCYCLOPROPYLCARBOXYLIC AMIDES AS POTASSIUM CHANNEL OPENERS | BRISTOL MYERS SQUIBB CO (US) | 2006-04-26 | — | — | EP | claimed |
| EP-1565190-A2 | ARYLCYCLOPROPYLCARBOXYLIC AMIDES AS POTASSIUM CHANNEL OPENERS | Bristol-Myers Squibb Company (US) | 2005-08-24 | — | — | EP | claimed |
| WO-2004047738-A2 | ARYLCYCLOPROPYLCARBOXYLIC AMIDES AS POTASSIUM CHANNEL OPENERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-10 | — | — | WO | claimed |
| CN-118290491-A | Copper nanocluster and preparation method thereof | 清华大学 | 2024-07-05 | — | — | CN | disclosed |
| US-20170158691-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | NOVIRA THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
| US-20170158691-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | NOVIRA THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
| US-9550779-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550779-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160185779-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
| CN-104884432-A | Alpha7 nicotinic acetylcholine receptor modulators and uses thereof-I | MERCK SHARP & DOHME | 2015-09-02 | — | — | CN | disclosed |
| US-8981049-B2 | Aziridine mediated native chemical ligation | WASHINGTON STATE UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-20130131311-A1 | AZIRIDINE MEDIATED NATIVE CHEMICAL LIGATION | WASHINGTON STATE UNIVERSITY (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2007025144-A1 | 5-HT2C RECEPTOR AGONISTS AS ANORECTIC AGENTS | UNIVERSITY OF ILLINOIS - CHICAGO (US) | 2007-03-01 | — | — | WO | disclosed |
| US-7144881-B2 | Arylcyclopropylcarboxylic amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1565190-A4 | ARYLCYCLOPROPYLCARBOXYLIC AMIDES AS POTASSIUM CHANNEL OPENERS | BRISTOL MYERS SQUIBB CO (US) | 2006-04-26 | — | — | EP | disclosed |
| EP-1565190-A2 | ARYLCYCLOPROPYLCARBOXYLIC AMIDES AS POTASSIUM CHANNEL OPENERS | Bristol-Myers Squibb Company (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004047738-A2 | ARYLCYCLOPROPYLCARBOXYLIC AMIDES AS POTASSIUM CHANNEL OPENERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131311-A1 | AZIRIDINE MEDIATED NATIVE CHEMICAL LIGATION | PTMS, NGLY1, DNPEP | FFAR1 2296/4885HDAC4 4706/4885ALDH1A1 1335/4885 |
| US-20170158691-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | HAVCR2, PYGL, HCCS | FFAR1 4075/4885HDAC4 1371/4885ALDH1A1 1370/4885 |
| US-20160185779-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | FFAR1 4075/4885HDAC4 1371/4885ALDH1A1 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.